The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: Overview of the evidence

Journal of Cardiovascular Surgery

Volumn 56, Issue 2, 2015, Pages 165-175

  Leunissen, T C ^a   De Borst, G J ^a   Janssen, P W A ^b   Ten Berg, J M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Blood platelets; Platelet aggregation inhibitors; Stenosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; VASODILATOR STIMULATED PHOSPHOPROTEIN; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING PARAMETERS; CAROTID ARTERY SURGERY; CAROTID REVASCULARIZATION; CORONARY ARTERY DISEASE; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; PERIOPERATIVE PERIOD; PLATELET REACTIVITY; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; THROMBOCYTE FUNCTION ANALYZER; ADVERSE EFFECTS; ANGIOPLASTY; BLEEDING; BLOOD; CAROTID ENDARTERECTOMY; CAROTID STENOSIS; CHEMICALLY INDUCED; DEVICES; DRUG EFFECTS; METABOLISM; PATIENT SELECTION; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; STENT; THROMBOCYTE; TREATMENT OUTCOME;

ANGIOPLASTY; BLOOD PLATELETS; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; HEMORRHAGE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 84938884657     PISSN: 00219509     EISSN: 1827191X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Biasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
2. Goodnight SH, Coull BM, McAnulty JH, Taylor LM. Antiplatelet therapy-Part II. West J Med 1993;158:506-14.
3. Hamish M, Gohel MS, Shepherd A, Howes NJ, Davies AH. Variations in the pharmacological management of patients treated with carotid endarterectomy: a survey of European vascular surgeons. Eur J Vasc Endovasc Surg 2009;38:402-7.
4. Bates ER, Babb JD, Casey DE Jr, Cates CU, Duckwiler GR, Feldman TE et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting). J Am Coll Cardiol 2007;49:126-70.
5. Wisman PP, Roest M, Asselbergs FW, De Groot PG, Moll FL, Van Der Graaf Y et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2014;12:736-47.
6. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J et al. Antiplatelet effects of Clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-6.
7. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325-9.
8. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D et al. Standard-ra. high-dose Clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
9. Montalescot G, Range G, Silvain J, Bonnet JL, Boueri Z, Barthélémy O et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. Circulation 2014;129:2136-43.
10. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013;167:2018-23.
11. Wang XD, Zhang DF, Zhuang SW, Lai Y. Modifying Clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with Clopidogrel resistance. Clin Cardiol 2011;34:332-8.
12. Bonello L, Camoin-Jau L, Arques S, Boy Er C, Panagides D, Wittenberg O et al. Adjusted Clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with Clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11.
13. Valgimigli M, Campo G, De Cesare N, Meliga E, Vranckx P, Furgieri A et al. Intensifying platelet inhibition with tiroflban in poor responders to aspirin, Clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tiroflban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22.
14. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
15. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U et al. A randomized trial of prasugrel versus Clopidogrel in patients with high platelet reactivity on Clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-64.
16. Payne DA, Jones CI, Hayes PD, Naylor AR, Goodall AH. Therapeutic benefit of low-close Clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight. Stroke 2007;38:2464-9.
17. Assadian A, Lax J, Meixner-Loicht U, Hagmuller GW, Bayer PM, Hubl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007;45:1142-7.
18. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR et al. Beneficial effects of Clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004;109:1476-81.
19. Payne DA, Jones CI, Hayes PD, Webster SE, Ross Naylor A, Goodall AH. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost 2004;92:89-96.
20. Hayes PD, Box H, Tull S, Bell PR, Goodall A, Naylor AR. Patients' thromboembolic potential after carotid endarterectomy is related to the platelets' sensitivity to adenosine diphosphate. J Vasc Surg 2003;38:1226-31.
21. Robless P, Okonko D, Tegos T, Mansfield A, Stansby G. Vascular surgical society of Great Britain and Ireland: platelet function during carotid endarterectomy and the antiplatelet effect of dextran 40. Br J Surg 1999;86:709.
22. Gonzalez A, Moniche F, Cayuela A, Gonzalez-Marcos JR, Mayol A, Montaner J. Antiplatelet effects of Clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting. J Vasc Surg 2014;60:428-35.
23. Nakagawa I, Wada T, Park HS, Nishimura F, Yamada S, Nakagawa H et al. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. J Vasc Surg 2014;59:761-7.
24. Sorkin GC, Dumont TM, Wach MM, Eller JL, Mokin M, Natarajan SK et al. Carotid artery stenting outcomes: do they correlate with antiplatelet response assays? J Neurointerv Surg 2014;6:373-8.
25. Fifl JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716-20.
26. Van Der Heyden J, Van Werkum J, Hackeng CM, Kelder JC, Breet NJ, Deneer VH et al. High versus standard Clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial. J Cardiovasc Surg (Torino) 2013;54:337-47.
27. Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNowP2Y12 Assay. InternMed 2011;50:695-8.
28. Muller-Schunk S, Linn J, Peters N, Spannagl M, Deisenberg M, Bruckmann H et al. Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786-791.
29. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-5.
30. Song TJ, Suh SH, Min PK, Kim DJ, Kim BM, Heo JH et al. The influence of anti-platelet resistanaepn the development of cerebral ischemic lesion after caroud artery stenting. Yonsei Med J 2013;54:288-94.
31. Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N, Varon D. Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate (let) analyzer (CPA) methods. Thromb Res 2001;1021:311-7.
32. Robless PA, Tegos TJ, Okonko D, Mansfield AO, Nicolaides AN, Mikhailidis DP et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002;13:231-9.
33. Janssen PW, Ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Trans Res 2013;6:316-28.
34. Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 2013;110:628-31.
35. Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patientsrationale and design of the patient outcome after primary PCI (POPular) genetics study. Am Heart J 2014;168:16-22.
36. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-19.
37. Hu YF, Lu TM, Wu CH, Lin YJ, Chang SL, Lo LW et al. Differences in high on-treatment platelet reactivity between intracoronary and peripheral blood after dual anti-platelet agents in patients with coronary artery disease. Thromb Haemost 2013;110:124-30.